Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 159

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 159
---
 )

    Other comprehensive loss, net of tax:

    Foreign currency translation adjustment

    189

    353

    Unrealized gain on marketable debt securities

    3

    150

    COMPREHENSIVE LOSS

    (18,390
    )

    (20,976
    )

    Less: Comprehensive (income) loss attributable to    noncontrolling interest

    (27
    )

    (7
    )

    COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE    COMMON SHAREHOLDERS
     
    $
    (18,417
    )
     
    $
    (20,983
    )

See accompanying notes to the consolidated financial statements.

99

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(IN THOUSANDS)

    Accumulated

    Other

    Total

    Common Shares

    Accumulated

    Noncontrolling

    Comprehensive

    Shareholders’

    Shares

    Amount

    Deficit

    Deficit

    Income / (Loss)

    Equity

    BALANCE - December 31, 2022

    170,093

    $
    440,280

    $
    (363,370
    )
     
    $
    (1,403
    )
     
    $
    (3,571
    )
     
    $
    71,936

    Shares issued through ATM financing

    4,775

    6,625

    —

    —

    —

    6,625

    Financing related fees

    —

    (221
    )

    —

    —

    —

    (221
    )

    Shares issued upon vesting of restricted stock units,    net of shares retired to pay employees’ taxes

    53

    (37
    )

    —

    —

    —

    (37
    )

    Shares issued upon exercise of stock options

    66

    56

    —

    —

    —

    56

    Stock-based compensation

    —

    4,640

    —

    —

    —

    4,640

    Unrealized gain on marketable debt securities

    —

    —

    —

    —

    150

    150

    Foreign currency translation adjustment

    —

    —

    —

    —